Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Brain-Aggregated and Body-Aggregated Alpha-Synuclein in Lewy Body Disease: Sowing Initial Seeds of Understanding.

Neurology·2026

Same author

A Bayesian network analysis of gait speed change upon transition to uneven surfaces in older adults.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026

Same author

Outcomes in Long-Term Follow-Up of Sporadic Parkinson's Disease in the Parkinson's Progression Markers Initiative.

Annals of neurology·2026

Same author

Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative.

Annals of neurology·2026

Same author

Cognitive Impairment in Parkinson's Disease: Contributions from the Parkinson's Progression Markers Initiative.

Annals of neurology·2026

Same author

Expanding PPMI through Remote Data Acquisition and Analysis: Early Success and Future Growth with myPPMI.

Annals of neurology·2026

Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026

Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026

Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026

Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026

Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026

Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 26, 2025

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Prodromal α-Synucleinopathies.

Continuum (Minneapolis, Minn.)

|October 12, 2022

Summary

This summary is machine-generated.

This review discusses prodromal alpha-synucleinopathies, which precede Parkinson disease and related disorders. Early identification and management of these conditions are crucial for at-risk individuals.

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Related Experiment Videos

Last Updated: Aug 26, 2025

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Area of Science:

Neurology
Neurodegenerative Diseases

Background:

Alpha-synucleinopathies, including Parkinson disease, multiple system atrophy, and dementia with Lewy bodies, are characterized by pathology that begins years before clinical diagnosis.
A prodromal phase may present with various signs or symptoms, and asymptomatic individuals may be at risk due to genetic or other factors.

Purpose of the Study:

To describe prodromal alpha-synucleinopathies.
To review the approach to patients in the prodromal or at-risk stages of alpha-synucleinopathies.

Main Methods:

Literature review of prodromal and at-risk alpha-synucleinopathies.
Analysis of clinical features, assessment strategies, and counseling approaches.

Main Results:

The prodromal phase of alpha-synucleinopathies is increasingly recognized in clinical settings.
Identifying individuals in the prodromal or at-risk stages is essential for timely intervention.

Conclusions:

Clinicians must be prepared to identify and manage patients in the prodromal or at-risk stages of alpha-synucleinopathies.
A comprehensive approach involving clinical feature identification, assessment, and counseling is necessary.